Evaluation of Barrett's esophagus with CK7, CK20, p53, Ki67, and COX2 expressions using chromoendoscopical examination

Diseases of the Esophagus

Volumn 26, Issue 2, 2013, Pages 189-196

  Coban S ^a   Ormeci N ^b   Savas B ^b   Ekiz, F ^a   Ensari, A ^b   Kuzu, I ^b   Palabiyikoglu M ^b  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Barrett's esophagus; Chromoendoscopy; Immunohistochemistry

Indexed keywords

CYCLOOXYGENASE 2; CYTOKERATIN 20; CYTOKERATIN 7; KI 67 ANTIGEN; METHYLENE BLUE; PROTEIN P53;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CELL PROLIFERATION; CHROMOENDOSCOPY; COLUMNAR EPITHELIUM; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; GASTROINTESTINAL DISEASE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; BIOPSY; COLORING AGENTS; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE 2; ESOPHAGOSCOPY; ESOPHAGUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; KERATIN-7; KI-67 ANTIGEN; MALE; METHYLENE BLUE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872924094     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2012.01352.x     Document Type: Article

References (46)

1. Haggitt R C. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994; 25: 982-93.
2. Avidan B, Sonnenberg A, Schnell T G etal. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97: 1930-6.
3. Koop H. Gastroesophageal reflux disease and Barrett's esophagus. Endoscopy 2004; 36: 103-9.
4. Ronkainen J, Aro P, Storskrubb T etal. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129: 1825-31.
5. Hage M, Siersema P D, van Dekken H etal. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004; 39: 1175-9.
6. Falk G W. Barrett's esophagus-is it bad for your health? Am J Gastroenterol 2005; 100: 2622-3.
7. Kerkhof M, van Dekken H, Steyerberg E W etal. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007; 50: 920-7.
8. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-22.
9. Hong M K, Laskin W B, Herman B E etal. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer 1995; 75: 423-9.
10. Gerdes J, Lelle R J, Pickartz H etal. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol 1986; 38: 977-80.
11. Ramires M, David L, Leitao D etal. Ki-67 labelling index in gastric carcinomas. An immunohistochemical study using double staining for the evaluation of the proliferative activity of diffuse-type carcinomas. J Pathol 1997; 182: 62-7.
12. Merola E, Mattioli E, Minimo C etal. Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's esophagus. J Cell Physiol 2006; 207: 512-9.
13. Krishnadath K K, van Blankenstein M, Tilanus H W. Prognostic value of p53 in Barrett's oesophagus. Eur J Gastroenterol Hepatol 1995; 7: 81-4.
14. Ohbu M, Kobayashi N, Okayasu I. Expression of cell cycle regulatory proteins in the multistep process of oesophageal carcinogenesis: stepwise over-expression of cyclin E and p53, reduction of p21(WAF1/CIP1) and dysregulation of cyclin D1 and p27(KIP1). Histopathology 2001; 39: 589-96.
15. Younes M, Lebovitz R M, Lechago L V etal. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993; 105: 1637-42.
16. Murray L, Sedo A, Scott M etal. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 2006; 55: 1390-7.
17. Vane J R, Botting R M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 2S-8S. discussion: 21S-2S.
18. Gilroy D W, Colville-Nash P R, Willis D etal. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5: 698-701.
19. Mizuno H, Sakamoto C, Matsuda K etal. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112: 387-97.
20. Crofford L J, Wilder R L, Ristimaki A P etal. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994; 93: 1095-101.
21. Tucker O N, Dannenberg A J, Yang E K, Fahey T J 3rd. Bile acids induce cyclooxygenase-2 expression in human pancreatic cancer cell lines. Carcinogenesis 2004; 25: 419-23.
22. Mehta S, Body A, Johnson I T, Rhodes M. Systematic review: cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. Aliment Pharmacol Ther 2006; 24: 1321-31.
23. Moll R. Cytokeratins in the histological diagnosis of malignant tumors. Int J Biol Markers 1997; 9: 63-9.
24. Ormeci N, Savas B, Coban S etal. The usefulness of chromoendoscopy with methylene blue in Barrett's metaplasia and early esophageal carcinoma. Surg Endosc 2008; 22: 693-700.
25. Hamilton S R, Vogelstein B, Kudo S etal. Tumours of the colon and rectum. In: Hamilton S R, Aaltonen L A, (eds). World Health Organization Classification of Tumours, Pathology & Genetics, Tumours of the Digestive System, 2nd edn. Lyon: IARC Press, 2000; 103-43.
26. Falk G W. Barrett's's esophagus. Gastroenterology 2002; 122: 1569-91.
27. Stein H J, Feith M, Siewert J R. Malignant degeneration of Barrett's esophagus: clinical point of view. Recent Results Cancer Res 2000; 155: 42-53.
28. Krishnadath K K, Tilanus H W, van Blankenstein M etal. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's's oesophagus. J Pathol 1995; 175: 175-80.
29. Klump B, Hsieh C J, Holzmann K etal. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's's esophagus: a longitudinal study. Z Gastroenterol 1999; 37: 1005-11.
30. Gimenez A, de Haro L M, Parrilla P etal. Immunohistochemical detection of p53 protein could improve the management of some patients with Barrett's esophagus and mild histologic alterations. Arch Pathol Lab Med 1999; 123: 1260-3.
31. Skacel M, Petras R E, Rybicki L A etal. p53 expression in low grade dysplasia in Barrett's's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol 2002; 97: 2508-13.
32. Moskaluk C A, Heitmiller R, Zahurak M etal. p53 and p21(WAF1/ CIP1/SDI1) gene products in Barrett's esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol 1996; 27: 1211-20.
33. Schneider P M, Casson A G, Levin B etal. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 1996; 111: 323-31.
34. Dvorak K, Ramsey L, Payne C M etal. Abnormal expression of biomarkers in incompletely ablated Barrett's esophagus. Ann Surg 2006; 244: 1031-36.
35. Krishnadath K K, Wang K K, Taniguchi K etal. Persistent genetic abnormalities in Barrett's's esophagus after photodynamic therapy. Gastroenterology 2000; 119: 624-30.
36. Coggi G, Bosari S, Roncalli M etal. p53 protein accumulation and p53 gene mutation in esophageal carcinoma: a molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997; 79: 425-32.
37. Feith M, Stein H J, Mueller J, Siewert J R. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. Dis Esophagus 2004; 17: 322-7.
38. Mulder A H, VanHootegem J C S, Sylvester R etal. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle related nuclear antigen (Ki-67). J Pathol 1992; 166: 37-43.
39. Hong M K, Laskin W B, Herman B E etal. Expansion of the Ki-67 proliferative compartment correlates with degree of dyspalsia in Barrett's esophagus. Cancer 1995; 75: 423-9.
40. Stein H J, Panel of Experts. Esophageal cancer: screening and surveillance. Results of a consensus conference. Dis Esophagus 1996; 9: 3-19.
41. Ormsby A H, Goldblum J R, Rice T W etal. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol 1999; 30: 288-94.
42. van Lier M G F, Bomhof F J, Leendertse I etal. CK phenotyping was not able to distinguish between cancer arising from a Barrett's oesophagus and carcinoma originating in the gastric cardia. J Clin Pathol 2005; 58: 722-4.
43. Nurgalieva Z, Lowrey A, El-Serag H B. The use of cytokeratin stain to distinguish Barrett's esophagus from contiguous tissues: a systematic review. Dig Dis Sci 2007; 52: 1345-54.
44. Wilson K T, Fu S, Ramanujam K S etal. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's's esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929-34.
45. Mehta S, Boddy A, Johnson I T, Rhodes M. Systematic review: cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. Aliment Pharmacol Ther 2006; 24: 1321-31.
46. Morris C D, Armstrong G R, Bigley G etal. Cyclooxygenase-2 expression in the Barrett's's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001; 96: 990-6.